Financials & Investment

₹110.90L CapEx →
INR 174.60-232.80L Revenue

Phase 1 revenue starts in Month 3 and scales through stabilization, with annual topline modeled under conservative and premium pricing scenarios from the feasibility report.

🏗️

₹110.90L

Total Phase 1 CapEx

📅

Month 3

First Revenue (Zone A Harvest)

💰

INR 18-24L/mo

Steady-State Monthly Revenue

📦

582 kg

Annual Pharma-Grade Output

📈

INR 174.60-232.80L

Projected Annual Revenue

🌱

≥10 mg/g

Cordycepin — Pharma-Grade Threshold

Phase 1 Revenue Projection

Monthly Revenue: Conservative vs Premium (INR Lakhs)

Phase 1 Capital Allocation

CapEx Breakdown (₹110.90 Lakhs Total)

Detailed CapEx Breakdown

Facility envelope & compliance

18%₹20.10L

Climate control (dual HVAC + TFA)

22%₹24.55L

Sterilization & autoclave machinery

9%₹9.70L

Production hardware & post-harvest

11%₹12.45L

Genetics lab & substrate (Cycle 1)

8%₹8.90L

AI, compute, sensing & power

17%₹19.20L

Admin & OpEx (deposit + 6-mo runway)

14%₹16.00L

Grand Total Launch Capital₹110.90 Lakhs

Revenue Model

Pricing Tiers & Market Positioning

Revenue projections use ₹30,000/kg (conservative) and ₹40,000/kg (premium export) as the per-kg rate — both within the Premium A-Grade tier.

₹5,000–₹10,000/kg

Low-Grade / Spent Waste

₹18,000–₹25,000/kg

Standard Raw Grade

₹30,000–₹45,000/kg

Premium A-Grade

Conservative model: ₹30K/kg

₹50,000–₹1,00,000/kg

Ultra-High / Export Grade

Premium model: ₹40K/kg

Seed Round · Open Now

₹30–50L

for 3.5–5.5% equity

Angel capital bridges Phase 0 → Phase 1 alongside a CGTMSE collateral-free government loan (₹50–60L) and BIRAC/KSUM grants post-prototype. Investor capital is deployed directly for facility construction and the first production cycle.

First commercial revenueMonth 3 (Zone A harvest)

Steady-state monthly revenueINR 18-24 Lakhs/month

Phase 1 annual revenueINR 174.60-232.80 Lakhs

Pricing scenariosConservative and premium annual revenue cases

Asset recovery timelineConservative: ~10 months · Premium: within Year 1

Express Interest →

Funding Sequence

Stage 1

Angel Investor

3.5–5.5% equity

₹30–50L

Stage 2

CGTMSE Loan

Collateral-free government loan

₹50–60L

Stage 3

BIRAC / KSUM

Grant funding post-prototype

TBD

Steady-State Monthly OPEX

Total monthly outflow₹6.92L/mo

Operations (substrate, utilities, logistics)₹3.30L

Staffing (4 specialists)₹1.80L

Facility & software₹0.72L

Debt service (CGTMSE EMI)₹1.08L

Breakeven at just 23.1 kg/month (conservative) — only 38% of steady-state capacity. At premium pricing, breakeven drops to 17.3 kg/month.

Use of Angel Funds

Facility construction & fit-out40%

HVAC & climate systems25%

AI compute & sensing stack20%

Working capital & 6-mo OpEx15%

Compliance = Competitive Moat

Regulatory Certifications Roadmap

Month 1

FSSAI Application Filed

High-risk manufacturing license, 60–90 days, ₹25–50K

Month 1

MSME/Udyam Registration

Required for CGTMSE loan eligibility. Free, immediate.

Month 3

First Master CoA

Third-party potency validation for each commercial batch

Month 5

First Export Pathway

Export documentation, phytosanitary review, and buyer qualification.

Year 1

GMP Fast-Track Application

Schedule M / WHO-GMP — pharma buyer unlock, ₹1.5–2.5Cr

Year 2

ISO 22000 Application

Leverages 12+ months of controlled Kryleos Atmos-OS batch records

Key Compliance Advantage: Physical unidirectional flow (pass-through autoclave, exit-only doors, de-gowning anteroom) structurally guarantees FSSAI high-risk hygiene compliance and structurally accelerates GMP and ISO 22000 audit readiness — blocking competitors who build conventionally.

Ready to Invest?

Schedule a call, request the full pitch deck, or come see the Phase 0 demo unit live.

Get In Touch →